79 related articles for article (PubMed ID: 21566428)
1. [Standardization of evaluation for target molecule in cancer therapy].
Ochiai A
Gan To Kagaku Ryoho; 2011 May; 38(5):709-14. PubMed ID: 21566428
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
[TBL] [Abstract][Full Text] [Related]
3. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH.
Das K; Gunasegaran B; Tan IB; Deng N; Lim KH; Tan P
Cancer Lett; 2014 Oct; 353(2):167-75. PubMed ID: 25086186
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors to targeted treatment in gastrointestinal carcinomas.
Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
[TBL] [Abstract][Full Text] [Related]
5. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
[TBL] [Abstract][Full Text] [Related]
6. [Molecular pathology - aspects in KRAS mutation analysis in colon carcinoma].
Hershkovitz D; Ben-lzhak O
Harefuah; 2013 Jun; 152(6):356-60, 367. PubMed ID: 23885470
[TBL] [Abstract][Full Text] [Related]
7. [I. Molecular targeted therapy for unresectable wild type K-ras recurrent colon cancer].
Hikosaka T; Yamazaki K
Gan To Kagaku Ryoho; 2013 Nov; 40(11):1456-8. PubMed ID: 24319791
[No Abstract] [Full Text] [Related]
8. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
[TBL] [Abstract][Full Text] [Related]
9. [Progress of targeted therapy related to K-ras mutation].
Li ZW; Liu YQ
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
[No Abstract] [Full Text] [Related]
10. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
Onozato R; Kosaka T; Kuwano H; Sekido Y; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
[TBL] [Abstract][Full Text] [Related]
11. Targeted treatment for lung cancer could be possible due to identification of nonuniform genetic mutations.
Jones S
Pharmacogenomics; 2014 May; 15(7):903-4. PubMed ID: 25090664
[No Abstract] [Full Text] [Related]
12. Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists.
Hoorens A; Jouret-Mourin A; Sempoux C; Demetter P; De Hertogh G; Teugels E
Acta Gastroenterol Belg; 2010; 73(4):497-503. PubMed ID: 21299161
[TBL] [Abstract][Full Text] [Related]
13. ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue.
Parsons BL; Marchant-Miros KE; Delongchamp RR; Verkler TL; Patterson TA; McKinzie PB; Kim LT
Cancer Invest; 2010 May; 28(4):364-75. PubMed ID: 20307197
[TBL] [Abstract][Full Text] [Related]
14. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.
Li Y; Wang J; Gao X; Han W; Zheng Y; Xu H; Zhang C; He Q; Zhang L; Li Z; Zhou D
PLoS One; 2014; 9(11):e113186. PubMed ID: 25427200
[TBL] [Abstract][Full Text] [Related]
15. Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases.
Bösmüller H; Kranewitter W; Webersinke G; Rumpold H; Hackl M; Fend F
Pathol Res Pract; 2011 Jun; 207(6):399-402. PubMed ID: 21536390
[TBL] [Abstract][Full Text] [Related]
16. [Correlation between the presence of Kras mutation and the presence of the proteins epiregulin and amphiregulin in colon cancer tissue].
Levi Y; Barshack I; Avivi K; Bar-ILan D; Gutman M; Aderka D; Berger R; Yacobi R
Harefuah; 2013 Jun; 152(6):326-9, 369. PubMed ID: 23885463
[TBL] [Abstract][Full Text] [Related]
17. EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy.
Thunnissen E; Bovée JV; Bruinsma H; van den Brule AJ; Dinjens W; Heideman DA; Meulemans E; Nederlof P; van Noesel C; Prinsen CF; Scheidel K; van de Ven PM; de Weger R; Schuuring E; Ligtenberg M
J Clin Pathol; 2011 Oct; 64(10):884-92. PubMed ID: 21947301
[TBL] [Abstract][Full Text] [Related]
18. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.
Li C; Sun Y; Fang R; Han X; Luo X; Wang R; Pan Y; Hu H; Zhang Y; Pao W; Shen L; Ji H; Chen H
J Thorac Oncol; 2012 Jan; 7(1):85-9. PubMed ID: 22071781
[TBL] [Abstract][Full Text] [Related]
19. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
20. Innovative personalized medicine in gastric cancer: time to move forward.
Lee J; Kim KM; Kang WK; Ou SH
Clin Genet; 2014 Jul; 86(1):37-43. PubMed ID: 24749947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
